Table 1.
Antimicrobial activity of meropenem/vaborbactam and comparator agents tested against organisms/organism groups
| Organism/antimicrobial agent | MIC50 (mg/L) | MIC90 (mg/L) | Percentage susceptible (%S)/percentage resistant (%R) using EUCAST criteriaa |
|||||
|---|---|---|---|---|---|---|---|---|
| Europe |
Eastern Europe |
Western Europe |
||||||
| %S | %R | %S | %R | %S | %R | |||
| Enterobacterales (n) | (6846) | (1724) | (5122) | |||||
| meropenem/vaborbactam | 0.03 | 0.06 | 98.0 | 2 | 92.7 | 7.3 | 99.8 | 0.2 |
| meropenem | 0.03 | 0.12 | 95.1 | 3.4 | 86.1 | 9.5 | 98.1 | 1.3 |
| imipenem | 0.25 | 2 | b | 3.9 | b | 10.3 | b | 1.7 |
| amikacin | 2 | 4 | 94.2c | 5.8 | 83.1c | 16.9 | 97.9c | 2.1 |
| aztreonam | ≤0.12 | >16 | 72.9 | 24.4 | 52.5 | 45 | 79.8 | 17.4 |
| cefepime | ≤0.5 | >16 | 77.4 | 18.9 | 53.8 | 42.3 | 85.3 | 11 |
| ceftazidime | 0.25 | >32 | 72.0 | 23.1 | 51.9 | 44.1 | 78.8 | 16 |
| colistin | ≤0.5 | >8 | 76.8 | 23.2 | 80.1 | 19.9 | 75.7 | 24.3 |
| gentamicin | ≤1 | >8 | 85.3c | 14.7 | 69.2c | 30.8 | 90.7c | 9.3 |
| levofloxacin | ≤0.12 | >4 | 75.0 | 21.9 | 55.4 | 40.6 | 81.5 | 15.6 |
| piperacillin/tazobactam | 2 | >64 | 75.6 | 19.4 | 59.8 | 34.2 | 80.9 | 14.4 |
| CRE (n) | (362) | (260) | (102) | |||||
| meropenem/vaborbactam | 4 | >32 | 63.0 | 37.0 | 51.5 | 48.5 | 92.2 | 7.8 |
| meropenem | 16 | >32 | 7.7 | 63.5 | 8.1 | 63.1 | 6.9 | 64.7 |
| imipenem | 8 | >8 | b | 71.8 | b | 68.1 | b | 81.4 |
| amikacin | 16 | >32 | 41.4c | 58.6 | 34.2c | 65.8 | 59.8c | 40.2 |
| aztreonam | >16 | >16 | 8.8 | 90.6 | 10.8 | 88.5 | 3.9 | 96.1 |
| cefepime | >16 | >16 | 4.7 | 90.6 | 5.8 | 90 | 2.0 | 92.2 |
| ceftazidime | >32 | >32 | 6.6 | 92.3 | 8.1 | 90.4 | 2.9 | 97.1 |
| colistin | ≤0.5 | >8 | 74.2 | 25.8 | 72.6 | 27.4 | 78.4 | 21.6 |
| gentamicin | >8 | >8 | 39.8c | 60.2 | 34.2c | 65.8 | 53.9c | 46.1 |
| levofloxacin | >4 | >4 | 8.9 | 88.1 | 6.6 | 90 | 14.7 | 83.3 |
| piperacillin/tazobactam | >64 | >64 | 0.3 | 99.4 | 0.4 | 99.6 | 0 | 99 |
| KPC-producing CRE (n) | (114) | (40) | (74) | |||||
| meropenem/vaborbactam | 0.12 | 1 | 99.1 | 0.9 | 97.5 | 2.5 | 100 | 0 |
| meropenem | 32 | >32 | 1.8 | 75.4 | 5.0 | 75 | 0 | 75.7 |
| imipenem | >8 | >8 | 3.5 | 92.1 | 10.0 | 87.5 | 0 | 94.6 |
| amikacin | 16 | >32 | 43.0c | 57 | 22.5c | 77.5 | 54.1c | 45.9 |
| aztreonam | >16 | >16 | 0 | 100.0 | 0 | 100.0 | 0 | 100.0 |
| cefepime | >16 | >16 | 0 | 99.1 | 0 | 100.0 | 0 | 98.6 |
| ceftazidime | >32 | >32 | 0 | 100.0 | 0 | 100.0 | 0 | 100.0 |
| colistin | ≤0.5 | >8 | 72.8 | 27.2 | 62.5 | 37.5 | 78.4 | 21.6 |
| gentamicin | 2 | >8 | 59.6c | 40.4 | 65.0c | 35 | 56.8c | 43.2 |
| levofloxacin | >4 | >4 | 4.4 | 94.7 | 0 | 97.5 | 6.8 | 93.2 |
| piperacillin/tazobactam | >64 | >64 | 0 | 99.1 | 0 | 100.0 | 0 | 98.6 |
| P. aeruginosa (n) | (3567) | (1310) | (2257) | |||||
| meropenem/vaborbactam | 0.5 | 32 | 82.1 | 17.9 | 69.2 | 30.8 | 89.7 | 10.3 |
| meropenem | 0.5 | 32 | 67.3 | 17.8 | 49.7 | 30.3 | 77.5 | 10.6 |
| imipenem | 1 | >8 | b | 31.1 | b | 48.9 | b | 20.8 |
| amikacin | 4 | >32 | 86.0c | 14 | 72.8c | 27.2 | 93.7c | 6.3 |
| aztreonam | 8 | >16 | b | 22.5 | b | 26.4 | b | 20.2 |
| cefepime | 4 | 16 | b | 23.7 | b | 33.8 | b | 17.8 |
| ceftazidime | 2 | >32 | b | 27 | b | 37.4 | b | 21 |
| colistin | 1 | 2 | 99.4 | 0.6 | 99.1 | 0.9 | 99.6 | 0.4 |
| gentamicin | 2 | >8 | ||||||
| levofloxacin | 1 | >4 | b | 42 | b | 57.2 | b | 33.2 |
| piperacillin/tazobactam | 8 | >64 | b | 30.6 | b | 40.9 | b | 24.5 |
| MDR P. aeruginosa (n) | (972) | (542) | (430) | |||||
| meropenem/vaborbactam | 16 | >32 | 41.0 | 59.0 | 31.5 | 68.5 | 53.0 | 47.0 |
| meropenem | 16 | >32 | 13.0 | 59.5 | 8.3 | 67.9 | 18.8 | 48.8 |
| imipenem | >8 | >8 | b | 79.8 | b | 87.8 | b | 69.8 |
| amikacin | 16 | >32 | 53.1c | 46.9 | 38.6c | 61.4 | 71.4c | 28.6 |
| aztreonam | >16 | >16 | b | 55.5 | b | 48.3 | b | 64.4 |
| cefepime | 16 | >16 | b | 76.4 | b | 78 | b | 74.4 |
| ceftazidime | 32 | >32 | b | 82 | b | 83 | b | 80.7 |
| colistin | 1 | 2 | 99.0 | 1.0 | 98.7 | 1.3 | 99.3 | 0.7 |
| gentamicin | >8 | >8 | ||||||
| levofloxacin | >4 | >4 | b | 90.9 | b | 94.6 | b | 86.3 |
| piperacillin/tazobactam | 64 | >64 | b | 93.3 | b | 91.7 | b | 95.3 |
a
Criteria as published by EUCAST.11
b
An arbitrary susceptible breakpoint of ≤0.001 mg/L and/or >50 mm has been published by EUCAST indicating that susceptible should not be reported for this organism/agent combination and intermediate should be interpreted as ‘susceptible increased exposure’.11 For imipenem with Enterobacterales, this decision applies to M. morgannii, Proteus spp. and Providencia spp.
c
For infections originating from the urinary tract. For systemic infections, aminoglycosides must be used in combination with another active therapy.